Interleukin-2 receptor antagonists and aggressive steroid minimization strategies for kidney transplant patients

Transplant International

Volumn 17, Issue 8, 2004, Pages 395-401

  Vincenti, Flavio ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Basiliximab; Corticosteroids; Daclizumab; IL 2 receptor antagonist; Renal

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CORTICOSTEROID; CYCLOSPORIN A; DACLIZUMAB; INTERLEUKIN 2 RECEPTOR ANTIBODY; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY;

ANEMIA; CLINICAL TRIAL; CORTICOSTEROID THERAPY; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG WITHDRAWAL; FOLLOW UP; GROWTH RETARDATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LEUKOPENIA; PATIENT SELECTION; PRIORITY JOURNAL; REVIEW; TREMOR;

ADRENAL CORTEX HORMONES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; RECEPTORS, INTERLEUKIN-2;

EID: 5444256681     PISSN: 09340874     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2004.tb00462.x     Document Type: Review

References (33)

1. Hricik DE, Shulak JA. Metabolic effects of steroid withdrawal in adult renal transplant recipients. Kidney Int 1993; 43 [Suppl]:S26.
2. Tejani A, Butt KM, Rajpoot D, et al. Strategies for optimizing growth in children wit kidney transplants. Transplantation 1989; 47:229.
3. Veenstra DL, Best JH, Hornberger J, et al. Incidence and long-term cost of steroid-related side effects after renal transplantation. Am J Kidney Dis 1999; 33:829.
4. Miller LW. Cardiovascular toxicities of immunosuppressive agents. Am J Transplant 2002; 2:807.
5. Lindholm A, Albrechtsen D, Frodin L, et al. Ischemic heart disease-major cause of death and graft loss after renal transplantation in Scandinavia. Transplantation 1995; 60:451.
6. Kavanagh D, Morris ST, Northridge DB, et al. Electrocardiogram and outcome following renal transplantation. Nephron 1999; 81:109.
7. Steroid Withdrawal Study Group. Prednisone withdrawal in kidney transplant recipients on cyclosporine and mycophenolate mofetil-a prospective randomized study. Transplantation 1999; 68:1865.
8. Hollander AA, Hene RJ, Hermans J, et al. Late prednisolone withdrawal in cyclosporine-treated kidney transplant patients: a randomized study. J Am Soc Nephrol 1997; 8:294.
9. Hricik DE, Bartucci MR, Moir EJ, et al. Effects of steroid withdrawal on post-transplant diabetes mellitus in cyclosporine-treated renal transplant recipients. Transplantation 1991; 51:374.
10. Hricik DE, Whalen CC, Lautman J, et al. Withdrawal of steroids after renal transplantation-clinical predictors of outcome. Transplantation 1992; 53:41.
11. Hricik DE, O'Toole MA, Schulak JA, et al. Steroid-free immunosuppression in cyclosporine-treated renal transplant recipients: a meta-analysis, J Am Soc Nephrol 1993; 4:1300.
12. Maiorca R, Cristinelli L, Brunori G, et al. Prospective controlled trial of steroid withdrawal after six months in renal transplant patients treated with cyclosporine. Transplant Proc 1988; 20:121.
13. Vanrenterghem Y, Lebranchu Y, Hene R, et al. for the Steroid Dosing Study Group. Double-blind comparison of two corticosteroid regimens plus mycophenolate mofetil and cyclosporine for prevention of acute renal allograft rejection. Transplantation 2000; 70:1352.
14. Squifflet J-P, Vanrenterghem Y, van Hooff JP, et al. and the European Tacrolimus/MMF Transplantation Study Group. Safe withdrawal of corticosteroids o mycophenolate mofetil: results of a large prospective multicenter, randomized study. Transplant Proc 2002; 34:1584.
15. Basadonna GP, Matas AJ, Gillingham KJ, et al. Early versus late acute renal allograft rejection: impact on chronic rejection. Transplantation 1993; 55:993.
16. Leggat JE, Ojo AO, Leichtman AB, et al. Long-term renal allograft survival: prognostic implication of the timing of acute rejection episodes. Transplantation 1997; 63:1268.
17. Almawi MY, Hess DA, Assi JW, et al. Pre-treatment with glucocorticoids enhance T-cell effector function: possible implications for immune rebound accompanying glucocorticoid withdrawal. Cell Transplant 1999; 8:637.
18. Cremer J, Struber M, Wagenbreth I, et al. Progression of steroid-associated osteoporosis after heart transplantation. Ann Thorac Surg 1999; 67:130.
19. Kovarik JM, Moore R, Wolf P, et al. Screening for basiliximab exposure-response relationships in renal allotransplantation. Clin Transplant 1999; 13:32.
20. Cherikh WS, Kauffman HM, Maghirang J, et al. A comparison of discharge immunosuppressive drug regimens in primary cadaveric kidney transplantation. Transplantation 2003; 76:463.
21. Webster AC, Playford EG, Higgins G, et al. Interleukin 2 receptor antagonists for renal transplant recipients: a meta-analysis of randomized trials. Transplantation 2004; 77:166.
22. Pisani F, Buonomo O, Iaria G, et al. Preliminary results of a prospective randomized study of basiliximab in kidney transplantation. Transplant Proc 2001; 33:2032.
23. Kuypers DR, Evenopoel P, Maes B, et al. The use of an anti-CD25 monoclonal antibody and mycophenolate mofetil enables the use of a low-dose tacrolimus and early withdrawal of steroids in renal transplant recipients. Clin Transplant 2003; 17:234.
24. Vincenti F, Monaco A, Grinyo J, et al. Multicenter randomized prospective trial of steroid withdrawal in renal transplant recipients receiving basiliximab, cyclosporin microemulsion and mycophenolate mofetil. Am J Transplant 2003; 3:306.
25. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55:713.
26. Rostaing L, Cantarovich D, Mourad G, et al. for the CARMEN Study Group. Steroid-free immunosuppression with a combination of daclizumab, tacrolimus and MMF is efficacious and safe: results of a large multicenter trial in renal transplantation. Am J Transplant 2003; 3 [Suppl 5]. Abstract 627.
27. Vitko S, Klinger M, Salmela K, et al. Comparison of two steroid-free regimens-basiliximab/tacrolimus and tacrolimus/MMF with tacrolimus/MMF/steroid therapy after renal transplantation. Am J Transplant 2003; 3 [Suppl 5]. Abstract 625.
28. Woodle ES, Vincenti F, Lorber M, et al. A multicenter open label pilot study of early (5 day) corticosteroid cessation in de novo renal transplant recipients under Simulect, tacrolimus and sirolimus therapy. Am J Transplant 2003; 3 [Suppl 5]. Abstract 1128.
29. Lee D, Xiao SG, Kumar A, et al. Tacrolimus (FK506) and cyclosporine (CsA) based steroid free immunosuppression in kidney transplant recipients-a comparative study of graft survival, graft function and chronic allograft nephropathy. Am J Transplant 2003; 3 [Suppl 3]. Abstract 784.
30. Cole E, Landsberg D, Russell D, et al. A pilot study of steroid-free immunosuppression in the prevention of acute rejection in renal allograft recipients. Transplantation 2001; 72:845.
31. Sarwal MM, Vidhun JR, Alexander SR, et al. Continued superior outcomes with modification and lengthened follow-up of a steroid-avoidance pilot with extended daclizumab induction in pediatric renal transplantation. Transplantation 2003; 76:1331.
32. Roozrohk HC, Chen L, Scandling JD, et al. Effect of steroid avoidance on early graft function after kidney transplantation. [Abstract #721] Amer J Transpl 2004; 4 [Suppl 8]:354.
33. Kumar MSA, Xiao SG, Fyfe B, et al. Corticosteroid free immunosuppression does not increase acute rejection or decrease two-year graft survival in African American kidney recipients-a controlled study. Am J Transplant 2003; 3 [Suppl 5]. Abstract 1126.